Anebulo Pharmaceuticals IncFRA Anebulo Stock Report

Anebulo Pharmaceuticals, Inc. engages in the provision of pharmaceutical services. The company is headquartered in Lakeway, Texas and currently employs 4 full-time employees. The company went IPO on 2021-05-07. The firm is engaged in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The Company’s lead product candidate is ANEB-001, a potent, small molecule cannabinoid receptor antagonist, to address the unmet medical need for a specific antidote for ACI. ANEB-001, is intended to rapidly reverse the negative effects of ACI within one hour of administration. The signs and symptoms of ACI range from profound sedation to anxiety and panic to psychosis with hallucinations. CB1 receptors are concentrated in the brain and central nervous system, while CB2 receptors are found mostly in peripheral organs and are associated with the immune system.